Eli Lilly deal shows there is high-quality IP in China for foreign businesses that are prepared to search it out

Suzhou-based biopharmaceuticals firm Innovent Biologics has entered into an alliance with Eli Lilly & Co which will see its cancer therapies developed and marketed worldwide by the US company in a deal potentially worth upwards of $456 million.

Get unlimited access to all IAM content